Health2Sync, AstraZeneca deploy digital aid for early detection of chronic kidney disease in Taiwan
Digital chronic disease management platform Health2Sync has signed a memorandum of understanding with pharmaceutical company AstraZeneca to launch a digital patient management program for patients with chronic kidney disease.
The digital program seeks to promote early diagnosis of CKD and optimize day-to-day CKD care using Health2Sync’s patient management platform.
According to a media release, the latest version of the patient management platform can automatically filter and categorize patients into different groups based on their lab reports. Through this platform, physicians can review long-term data analysis and trends of patients at risk for CKD, helping to inform their medical interventions.
The platform has a companion mobile app that patients can use to consult with care providers about adjustments in their medication regimen.
WHY IT IMPORTANT
Taiwan is spending nearly $1.8 billion a year on CKD, making it the most costly illness for the National Health Insurance system. According to Claudio Longo, president of AstraZeneca Taiwan, the company hopes the partnership with Health2Sync will help reduce healthcare costs by empowering doctors to identify patients early and manage their conditions well. than. Early recognition of CKD can also help prevent its progression and reduce the risk of complications.
Health2Sync is developing a portfolio of digital therapies that currently includes insulin management and behavior change. The latest partnership with AstraZeneca represents their first foray into CKD.
CEO and co-founder Ed Deng said years of experience helping improve outcomes for diabetics with the Health2Sync app “proven that data integration and digital interventions can be applied.” more for other chronic diseases”.
TREND TO BIGGER
Two years ago, AstraZeneca participated in a Research collaboration with New York-based Renalytix AI, which involved using the AI KidneyIntelX-powered in vitro diagnostic platform to collect patient data to generate a patient’s CKD risk score. Risk scores can aid doctors in predicting disease progression and inform treatments to prevent decline in kidney function.
Another CKD-focused digital initiative in Asia is My Kidney Journey website developed and launched by dialysis care solutions developer Baxter Asia Pacific last November. The website is an online repository of information about CKD to support patients and their families and carers.
In other news, Health2Sync signed a cooperation with Sanofi a few weeks ago to bring digital solutions for insulin management to Japan. In March, the Taiwanese company affiliated with the Danish pharmaceutical company Novo Nordisk to integrate its mobile disease management app with NovoPen 6 and NovoPen Echo Plus.
